KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cineverse (CNVS) Current Deferred Revenue (2016 - 2025)

Cineverse filings provide 15 years of Current Deferred Revenue readings, the most recent being $100000.0 for Q2 2025.

  • On a quarterly basis, Current Deferred Revenue fell 66.67% to $100000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $100000.0, a 66.67% decrease, with the full-year FY2025 number at $200000.0, down 54.13% from a year prior.
  • Current Deferred Revenue hit $100000.0 in Q2 2025 for Cineverse, down from $200000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $924000.0 in Q1 2021 to a low of $100000.0 in Q2 2025.
  • Median Current Deferred Revenue over the past 5 years was $285000.0 (2021), compared with a mean of $313411.8.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 78.79% in 2022 and later surged 92.92% in 2024.
  • Cineverse's Current Deferred Revenue stood at $285000.0 in 2021, then dropped by 5.26% to $270000.0 in 2022, then dropped by 25.93% to $200000.0 in 2023, then soared by 65.5% to $331000.0 in 2024, then crashed by 69.79% to $100000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $100000.0 (Q2 2025), $200000.0 (Q1 2025), and $331000.0 (Q4 2024) per Business Quant data.